95 related articles for article (PubMed ID: 9443417)
1. Both autocrine and paracrine effects of transfected acidic fibroblast growth factor are involved in the estrogen-independent and antiestrogen-resistant growth of MCF-7 breast cancer cells.
Zhang L; Kharbanda S; Hanfelt J; Kern FG
Cancer Res; 1998 Jan; 58(2):352-61. PubMed ID: 9443417
[TBL] [Abstract][Full Text] [Related]
2. FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation.
Wellberg EA; Kabos P; Gillen AE; Jacobsen BM; Brechbuhl HM; Johnson SJ; Rudolph MC; Edgerton SM; Thor AD; Anderson SM; Elias A; Zhou XK; Iyengar NM; Morrow M; Falcone DJ; El-Hely O; Dannenberg AJ; Sartorius CA; MacLean PS
JCI Insight; 2018 Jul; 3(14):. PubMed ID: 30046001
[TBL] [Abstract][Full Text] [Related]
3. Expression of Q227L-galphas in MCF-7 human breast cancer cells inhibits tumorigenesis.
Chen J; Bander JA; Santore TA; Chen Y; Ram PT; Smit MJ; Iyengar R
Proc Natl Acad Sci U S A; 1998 Mar; 95(5):2648-52. PubMed ID: 9482941
[TBL] [Abstract][Full Text] [Related]
4. FGF1 supports glycolytic metabolism through the estrogen receptor in endocrine-resistant and obesity-associated breast cancer.
Castillo-Castrejon M; Sankofi BM; Murguia SJ; Udeme AA; Cen HH; Xia YH; Thomas NS; Berry WL; Jones KL; Richard VR; Zahedi RP; Borchers CH; Johnson JD; Wellberg EA
Breast Cancer Res; 2023 Aug; 25(1):99. PubMed ID: 37608351
[TBL] [Abstract][Full Text] [Related]
5. Ligand activation of alternatively spliced fibroblast growth factor receptor-1 modulates pancreatic adenocarcinoma cell malignancy.
Vickers SM; Huang ZQ; MacMillan-Crow L; Greendorfer JS; Thompson JA
J Gastrointest Surg; 2002; 6(4):546-53. PubMed ID: 12127120
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic Ras-induced proliferation requires autocrine fibroblast growth factor 2 signaling in skeletal muscle cells.
Fedorov YV; Rosenthal RS; Olwin BB
J Cell Biol; 2001 Mar; 152(6):1301-5. PubMed ID: 11257129
[TBL] [Abstract][Full Text] [Related]
7. FGFR1 Signaling Facilitates Obesity-Driven Pulmonary Outgrowth in Metastatic Breast Cancer.
Kulkoyluoglu Cotul E; Safdar MH; Paez SJ; Kulkarni A; Ayers MG; Lin H; Xianyu Z; Teegarden D; Hursting SD; Wendt MK
Mol Cancer Res; 2024 Mar; 22(3):254-267. PubMed ID: 38153436
[TBL] [Abstract][Full Text] [Related]
8. Challenges and opportunities in the targeting of fibroblast growth factor receptors in breast cancer.
Jain VK; Turner NC
Breast Cancer Res; 2012 Jun; 14(3):208. PubMed ID: 22731805
[TBL] [Abstract][Full Text] [Related]
9. Computational model and microfluidic platform for the investigation of paracrine and autocrine signaling in mouse embryonic stem cells.
Ellison D; Munden A; Levchenko A
Mol Biosyst; 2009 Sep; 5(9):1004-12. PubMed ID: 19668866
[TBL] [Abstract][Full Text] [Related]
10. Receptor FGFRL1 acts as a tumor suppressor in nude mice when overexpressed in HEK 293 Tet-On cells.
Zhuang L; Steinberg F; Trueb B
Oncol Lett; 2016 Dec; 12(6):4524-4530. PubMed ID: 28101211
[TBL] [Abstract][Full Text] [Related]
11. FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells.
Zhao M; Zhuo ML; Zheng X; Su X; Meric-Bernstam F
Oncotarget; 2019 Jan; 10(1):30-44. PubMed ID: 30713601
[TBL] [Abstract][Full Text] [Related]
12. Corrigendum to "Scattered DUSP28 is a novel biomarker responsible for aggravating malignancy via the autocrine and paracrine signaling in metastatic pancreatic cancer" [Cancer Lett. 456 (2019 Aug 1) 1-12].
Lee J; Lee J; Kim JH
Cancer Lett; 2024 Feb; 583():216454. PubMed ID: 38044256
[No Abstract] [Full Text] [Related]
13. FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice.
Kommalapati A; Tella SH; Borad M; Javle M; Mahipal A
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34199304
[TBL] [Abstract][Full Text] [Related]
14. Targeting fibroblast growth factor receptors to combat aggressive ependymoma.
Lötsch D; Kirchhofer D; Englinger B; Jiang L; Okonechnikov K; Senfter D; Laemmerer A; Gabler L; Pirker C; Donson AM; Bannauer P; Korbel P; Jaunecker CN; Hübner JM; Mayr L; Madlener S; Schmook MT; Ricken G; Maaß K; Grusch M; Holzmann K; Grasl-Kraupp B; Spiegl-Kreinecker S; Hsu J; Dorfer C; Rössler K; Azizi AA; Foreman NK; Peyrl A; Haberler C; Czech T; Slavc I; Filbin MG; Pajtler KW; Kool M; Berger W; Gojo J
Acta Neuropathol; 2021 Aug; 142(2):339-360. PubMed ID: 34046693
[TBL] [Abstract][Full Text] [Related]
15. The Extracellular Matrix and Vesicles Modulate the Breast Tumor Microenvironment.
Yang J; Bahcecioglu G; Zorlutuna P
Bioengineering (Basel); 2020 Oct; 7(4):. PubMed ID: 33050609
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1.
Zhu Y; Liu Y; Zhang C; Chu J; Wu Y; Li Y; Liu J; Li Q; Li S; Shi Q; Jin L; Zhao J; Yin D; Efroni S; Su F; Yao H; Song E; Liu Q
Nat Commun; 2018 Apr; 9(1):1595. PubMed ID: 29686231
[TBL] [Abstract][Full Text] [Related]
17. Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors.
Wheler JJ; Atkins JT; Janku F; Moulder SL; Stephens PJ; Yelensky R; Valero V; Miller V; Kurzrock R; Meric-Bernstam F
Oncoscience; 2016; 3(5-6):164-72. PubMed ID: 27489863
[TBL] [Abstract][Full Text] [Related]
18. Exposures to synthetic estrogens at different times during the life, and their effect on breast cancer risk.
Hilakivi-Clarke L; de Assis S; Warri A
J Mammary Gland Biol Neoplasia; 2013 Mar; 18(1):25-42. PubMed ID: 23392570
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition.
Fischer H; Taylor N; Allerstorfer S; Grusch M; Sonvilla G; Holzmann K; Setinek U; Elbling L; Cantonati H; Grasl-Kraupp B; Gauglhofer C; Marian B; Micksche M; Berger W
Mol Cancer Ther; 2008 Oct; 7(10):3408-19. PubMed ID: 18852144
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor reduces tamoxifen efficacy and promotes metastatic colonization and desmoplasia in breast tumors.
Qu Z; Van Ginkel S; Roy AM; Westbrook L; Nasrin M; Maxuitenko Y; Frost AR; Carey D; Wang W; Li R; Grizzle WE; Thottassery JV; Kern FG
Cancer Res; 2008 Aug; 68(15):6232-40. PubMed ID: 18676847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
